Why specialty pharmacy is the most controllable leak in the health budget
For most employers, the pharmacy line now grows faster than hospital claims. That shift is driven by specialty drugs, GLP‑1 drug therapies for weight management and diabetes, and oncology drugs that sit under both the medical benefit and the pharmacy benefit. When you look at total health care costs, specialty drug costs are often the single largest unmanaged exposure in the entire health plan.
The uncomfortable truth is that specialty drug cost management for any employer is both the most controllable and the most opaque part of healthcare spend. Traditional pharmacy benefits were built for cheap retail drugs, not for high cost specialty drugs that can reach six figures per member per year and distort expected trend. Yet many employers still treat drug spend as a pass through item, trusting a pharmacy benefit manager to handle drug management without rigorous utilization management or data transparency.
In a typical managed care arrangement, the same vendor designs the pharmacy benefits, controls the specialty pharmacy network, and reports on pharmacy trend. That concentration of power makes it hard for benefits leaders to see the real drug costs, especially when spread pricing and opaque rebates hide the true cost of care. A credible specialty drug cost management employer strategy starts with reclaiming the data, separating medical pharmacy from retail pharmacy reporting, and forcing line of sight into every euro of drug costs and every member level utilization pattern.
PBM contracts, spread pricing and why the annual trend report is not enough
Most employers still sign pharmacy contracts that would not pass basic procurement scrutiny in any other category. The pharmacy benefit manager controls the drug formulary, the specialty pharmacy channel, and the medical pharmacy claims feed, yet the employer often sees only a glossy trend report. That is a fragile position for any specialty drug cost management employer that is trying to manage health plan costs and protect member health.
Spread pricing is the first leak to close in pharmacy benefits management. Under spread pricing, the PBM bills the health plan one drug cost while paying the dispensing pharmacy a lower amount, keeping the spread as revenue and obscuring the real costs of drugs. Employers that move to a transparent or pass through pharmacy benefit model, with clear administrative fees and full access to claims data, usually find that their drug spend and pharmacy trend look very different from what they were told.
Rebates are the second leak, especially for specialty drugs and GLP‑1 drugs where list prices are high and rebate structures complex. A sophisticated specialty drug cost management employer will insist on full rebate guarantees, audit rights, and the ability to see how rebates influence formulary placement and member cost sharing. That same employer will also benchmark contract terms against independent pharmacy benefit audits, rather than relying on a single PBM narrative about managed care performance and drug management outcomes.
Designing a specialty and oncology strategy that aligns cost, care and equity
Once the contract is under control, the next frontier is clinical design for specialty drugs and oncology therapies. Here, the specialty drug cost management employer must integrate medical benefit policies, pharmacy benefit rules, and site of care strategies into one coherent health plan approach. Without that integration, high cost infused drugs will leak through the medical pharmacy channel while oral specialty drugs quietly inflate pharmacy trend.
Formulary management is the first lever, especially as the drug pipeline fills with biosimilars and new oncology drugs. Employers should require their pharmacy benefit manager and any specialty pharmacy partner to prioritize clinically appropriate biosimilars, use step therapy where evidence supports it, and align member cost sharing with value rather than list price. Site of care redirection, moving infusions from hospital outpatient departments to lower cost ambulatory centers or home care when safe, can cut drug costs by 30 to 50 percent for some medical pharmacy claims.
Utilization management must be precise, not punitive, and grounded in FDA labeling and specialty care guidelines. Prior authorization criteria should be transparent to both prescribers and members, with clear appeal pathways and protections for vulnerable patients with complex health conditions. When employers align oncology management, specialty pharmacy oversight, and medical benefit policies, they not only reduce expected costs but also create a more coherent health care experience for every member navigating specialty drugs.
GLP-1 coverage decisions that protect both member health and the plan budget
GLP‑1 drugs have become the emblem of runaway pharmacy costs, but they also offer meaningful health benefits for diabetes and obesity when used appropriately. A thoughtful specialty drug cost management employer will not default to blanket exclusions or unlimited coverage; instead, it will define clear eligibility criteria tied to medical need and evidence based care. That means differentiating between GLP‑1 use for diabetes management under the medical benefit and GLP‑1 use for weight loss under the pharmacy benefit, with distinct utilization management rules.
Step therapy can play a role, but only if it respects clinical standards and avoids unnecessary delays in care. Employers should work with their pharmacy benefit manager, medical pharmacy team, and specialty pharmacy partners to require lifestyle interventions and lower cost drugs where appropriate, while still covering GLP‑1 drugs for members who meet defined health risk thresholds. Outcome tracking is essential; plans should monitor weight loss, A1C changes, and downstream medical costs to see whether GLP‑1 coverage is actually improving health care outcomes and reducing long term drug spend.
Equity must sit alongside cost and clinical effectiveness in GLP‑1 strategy. If only higher paid employees can afford GLP‑1 cost sharing, the health plan will widen disparities in obesity and diabetes outcomes across the workforce. Employers that integrate GLP‑1 policies into a broader chronic condition management program, with aligned pharmacy benefits, managed care support, and transparent communication, will see more sustainable drug costs and better member trust in the overall health plan.
Auditing performance and building a governance model that actually holds
No specialty drug cost management employer strategy is credible without independent auditing and strong internal governance. Relying on a single annual trend report from the pharmacy benefit manager is not governance; it is delegation without verification. Employers should commission periodic audits of pharmacy benefits, medical pharmacy claims, and specialty pharmacy performance, using external actuaries or pharmacy consultants who are not tied to the incumbent vendor.
Those audits should examine drug costs at the claim level, compare paid amounts to benchmark data, and test whether utilization management rules are applied consistently across members. They should also review how the PBM handles high cost specialty drugs, GLP‑1 utilization, and oncology care under both the medical benefit and the pharmacy benefit. When employers see the full data picture, they can renegotiate contracts, adjust formularies, and refine managed care strategies with far more confidence.
Governance also means aligning internal stakeholders around pharmacy benefits as a strategic lever, not a back office function. Finance, HR, and clinical advisors should review pharmacy trend, drug pipeline forecasts, and specialty pharmacy metrics at least quarterly, treating drug management as a core part of health care strategy. When that happens, the pharmacy budget stops being a mysterious black box and becomes a disciplined, measurable component of total rewards — not another merit matrix, but an actual retention lever.
FAQ
How can employers get better visibility into specialty drug costs ?
Employers can require full claims level data from their pharmacy benefit manager, including both retail and medical pharmacy claims for specialty drugs. Independent audits that compare paid amounts to market benchmarks help reveal hidden spreads and fees. Regular internal reviews of pharmacy trend and high cost claimants then turn that data into actionable management decisions.
What is the difference between medical benefit and pharmacy benefit coverage for specialty drugs ?
Specialty drugs administered in a clinic or hospital, such as many oncology infusions, are usually billed under the medical benefit. Self administered specialty drugs, including many GLP‑1 therapies, typically run through the pharmacy benefit. Understanding which channel pays which drug is critical, because unit costs, member cost sharing, and utilization management rules often differ significantly.
Are GLP-1 drugs worth the cost for employer health plans ?
GLP‑1 drugs can be cost effective when targeted to members with significant obesity or diabetes related risks and when paired with lifestyle support. Plans that set clear eligibility criteria, use step therapy appropriately, and track outcomes over time are more likely to see reduced downstream medical costs. Unlimited GLP‑1 coverage without utilization management, by contrast, tends to drive unsustainable pharmacy trend.
How often should employers audit their pharmacy benefit manager ?
Most large employers benefit from a comprehensive PBM audit every two to three years, with lighter annual reviews of key metrics such as rebates, discounts, and specialty drug utilization. Audits should cover contract compliance, pricing guarantees, and the application of utilization management rules. Smaller employers can often participate in coalition audits to gain similar oversight at lower cost.
What role does specialty pharmacy play in managing high cost drugs ?
Specialty pharmacy providers focus on complex, high cost drugs that require intensive clinical support, such as oncology and GLP‑1 therapies. They can improve adherence, manage side effects, and coordinate care with prescribers, which may reduce avoidable medical costs. Employers should ensure that their specialty pharmacy network is integrated with both medical and pharmacy benefits so that member care and cost controls remain aligned.